5 completed, 2 not yet recruiting, 2 recruiting, 1 withdrawn. 4 Phase 1, 3 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 4 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow enarodustat: new trials by email Literature Review of enarodustat trials Research Report on enarodustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enarodustat+CsA vs CsA in the Treatment of Newly-diagnosed TD-NSAA Enarodustat, Cyclosporin (CSA) - Transfusion-dependent Non-severe Aplastic Anemia | Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA Enarodustat, Cyclosporine (CsA) - Transfusion-dependent Non-severe Aplastic Anemia | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 90 | 2026-04-01 | 2026-04-23 |
| Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients Enarodustat 2mg, Enarodustat 3mg, Enarodustat 4mg - Renal Anemia in Non-dialysis Chronic Kidney Disease | Phase 4 | Not yet recruiting | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 120 | 2025-08-01 | 2025-07-23 |
| Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease Enarodustat - Chronic Kidney Disease Associated Anemia | Phase 4 | Recruiting | Shanghai Zhongshan Hospital | 1670 | 2025-03-27 | 2025-07-28 |
| Real-World Study of Enarodustat for Anemia in Non-Dialysis CKD Patients Enarodustat - Anemia of Chronic Kidney Disease, CKD | Recruiting | Huashan Hospital | 90 | 2025-03-23 | 2026-08-03 | |
| A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis. JTZ-951, Darbepoetin Alfa - Anemia of Chronic Kidney Disease | Phase 3 | Completed | JW Pharmaceutical | 172 | 2019-01-15 | 2021-03-22 |
| Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis JTZ-951, 14C-JTZ-951 - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 6 | 2016-06-01 | 2016-11-29 |
| Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease JTZ-951, Lapatinib - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 10 | 2015-10-01 | 2016-04-28 |
| Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease JTZ-951 - Anemia in Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 6 | 2013-10-01 | 2014-03-18 |
| Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease JTZ-951, Placebo - Anemia of Chronic Kidney Disease | Phase 1 | Completed | Akros Pharma Inc. | 29 | 2013-05-01 | 2014-07-14 |
Anemia (2) · Renal Insufficiency, Chronic (2) · Inflammation (1) · Kidney Failure, Chronic (1)
Akros Pharma Inc. (4) · Peking Union Medical College Hospital (2) · Huashan Hospital (1) · JW Pharmaceutical (1) · Shanghai Zhongshan Hospital (1) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (1)
United States (4) · China (3) · South Korea (1)
Hideyuki Yamamoto (2) · Jing Chen, PhD, MD (1) · Xiaoqiang Ding (1)